Suzanne C Cannegieter

List of Publications by Year
in descending order

288 papers	16,848 citations	23567 58 h-index	17592 121 g-index
293 all docs	293 docs citations	293 times ranked	16056 citing authors

#	Article	IF	Citations
1	A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 1993, 69, 236-239.	3.4	1,658
2	Incidence and mortality of venous thrombosis: a population-based study. Journal of Thrombosis and Haemostasis, 2007, 5, 692-699.	3.8	1,134
3	Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses.. Circulation, 1994, 89, 635-641.	1.6	932
4	Epidemiology of cancer-associated venous thrombosis. Blood, 2013, 122, 1712-1723.	1.4	914
5	Optimal Oral Anticoagulant Therapy in Patients with Mechanical Heart Valves. New England Journal of Medicine, 1995, 333, 11-17.	27.0	846
6	A method to determine the optimal intensity of oral anticoagulant therapy. Thrombosis and Haemostasis, 1993, 69, 236-9.	3.4	659
7	Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events. JAMA - Journal of the American Medical Association, 2005, 293, 2352.	7.4	489
8	Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1480-1483.	3.8	410
9	Use of Glucocorticoids and Risk of Venous Thromboembolism. JAMA Internal Medicine, 2013, 173, 743.	5.1	349
10	Incidence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism: a contemporary view of the published literature. European Respiratory Journal, 2017, 49, 1601792.	6.7	339
11	Multisystem Morbidity and Mortality in Cushing's Syndrome: A Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2277-2284.	3.6	324
12	Pulmonary embolism. Nature Reviews Disease Primers, 2018, 4, 18028.	30.5	208
13	Risk factors for venous thrombosis â€“ current understanding from an epidemiological point of view. British Journal of Haematology, 2010, 149, 824-833.	2.5	174
14	Activation of coagulation system during air travel: a crossover study. Lancet, The, 2006, 367, 832-838.	13.7	162
15	Incidence of Venous Thromboembolism in Patients with Cushing's Syndrome: A Multicenter Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3525-3532.	3.6	161
16	Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?. Thrombosis Research, 2020, 193, 86-89.	1.7	156
17	Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. British Journal of Haematology, 2007, 138, 769-774.	2.5	154
18	Travel-Related Venous Thrombosis: Results from a Large Population-Based Case Control Study (MEGA) Tj ETQq0 0 0 rgBT /Overlock 10 T	8.4	145

#	Article	IF	Citations
19	Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation, 2019, 139, 775-786.	1.6	129
20	The Absolute Risk of Venous Thrombosis after Air Travel: A Cohort Study of 8,755 Employees of International Organisations. PLoS Medicine, 2007, 4, e290.	8.4	118
21	Sex Difference in Risk of Second but Not of First Venous Thrombosis. Circulation, 2014, 129, 51-56.	1.6	114
22	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. Circulation, 2017, 135, 7-16.	1.6	114
23	Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. New England Journal of Medicine, 2017, 376, 515-525.	27.0	113
24	Association of Mild to Moderate Chronic Kidney Disease With Venous Thromboembolism. Circulation, 2012, 126, 1964-1971.	1.6	109
25	Travel and venous thrombosis: a systematic review. Journal of Internal Medicine, 2007, 262, 615-634.	6.0	107
26	Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment. Journal of Thrombosis and Haemostasis, 2014, 12, 1593-1600.	3.8	103
27	Outcome After ST Elevation Myocardial Infarction in Patients With Cancer Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2013, 112, 1867-1872.	1.6	98
28	Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave. Thrombosis Research, 2021, 199, 143-148.	1.7	98
29	Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis: Incidence and Predictors. PLoS Medicine, 2012, 9, e1001155.	8.4	96
30	Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based. Blood, 2008, 111, 4471-4476.	1.4	94
31	Arterial cardiovascular risk factors and venous thrombosis: results from a population-based, prospective study (the HUNT 2). Haematologica, 2010, 95, 119-125.	3.5	92
32	Acute cardiovascular events and all-cause mortality in patients with hyperthyroidism: a population-based cohort study. European Journal of Endocrinology, 2017, 176, 1-9.	3.7	91
33	Broadening the factor V Leiden paradox: pulmonary embolism and deep-vein thrombosis as 2 sides of the spectrum. Blood, 2012, 120, 933-946.	1.4	90
34	Intramyocardial Injection of Autologous Bone Marrow-Derived Ex Vivo Expanded Mesenchymal Stem Cells in Acute Myocardial Infarction Patients is Feasible and Safe up to 5ÂYears of Follow-up. Journal of Cardiovascular Translational Research, 2013, 6, 816-825.	2.4	90
35	Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients. Europace, 2011, 13, 389-394.	1.7	87
36	Relationship between Venous and Arterial Thrombosis: A Review of the Literature from a Causal Perspective. Seminars in Thrombosis and Hemostasis, 2011, 37, 885-896.	2.7	86

#	Article	IF	Citations
37	Sex difference in risk of recurrent venous thrombosis and the risk profile for a second event. Journal of Thrombosis and Haemostasis, 2010, 8, 2159-2168.	3.8	83
38	Hematologic variables and venous thrombosis: red cell distribution width and blood monocyte count are associated with an increased risk. Haematologica, 2014, 99, 194-200.	3.5	83
39	The risk of venous thrombosis in women over 50â€ƒyears old using oral contraception or postmenopausal hormone therapy. Journal of Thrombosis and Haemostasis, 2013, 11, 124-131.	3.8	80
40	Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested caseâ€"control study. Journal of Thrombosis and Haemostasis, 2014, 12, 1207-1215.	3.8	80
41	Towards a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1040-1043.	3.8	80
42	Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. Haemophilia, 2015, 21, 505-512.	2.1	77
43	High levels of coagulation factors and venous thrombosis risk: strongest association for factorÂVIII and von Willebrand factor. Journal of Thrombosis and Haemostasis, 2019, 17, 99-109.	3.8	77
44	Quantification of Bias in Direct Effects Estimates Due to Different Types of Measurement Error in the Mediator. Epidemiology, 2012, 23, 551-560.	2.7	73
45	The influence of thyroid function on the coagulation system and its clinical consequences. Journal of Thrombosis and Haemostasis, 2018, 16, 634-645.	3.8	73
46	Risk of Cerebral Venous Thrombosis in Obese Women. JAMA Neurology, 2016, 73, 579.	9.0	72
47	Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. Journal of Thrombosis and Haemostasis, 2013, 11, 116-123.	3.8	71
48	The clinical course of patients with implantable cardioverter-defibrillators: Extended experience on clinical outcome, device replacements, and device-related complications. Heart Rhythm, 2015, 12, 1169-1176.	0.7	71
49	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS ONE, 2015, 10, e0122520.	2.5	69
50	Cardiac device infections are associated with a significant mortality risk. Heart Rhythm, 2012, 9, 494-498.	0.7	68
51	Inflammatory Cytokines as Risk Factors for a First Venous Thrombosis: A Prospective Population-Based Study. PLoS Medicine, 2006, 3, e334.	8.4	67
52	Healthcare and disease burden among refugees in long-stay refugee camps at Lesbos, Greece. European Journal of Epidemiology, 2017, 32, 851-854.	5.7	67
53	Optimal intensity of oral anticoagulant therapy after myocardial infarction. Journal of the American College of Cardiology, 1996, 27, 1349-1355.	2.8	65
54	A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). Journal of Thrombosis and Haemostasis, 2006, 4, 44-49.	3.8	63

#	Article	IF	Citations
55	Increasing levels of free thyroxine as a risk factor for a first venous thrombosis: a case-control study. Blood, 2010, 115, 4344-4349.	1.4	63
56	Predictive value of factorÂVIII levels for recurrent venous thrombosis: results from the MEGA followâ€up study. Journal of Thrombosis and Haemostasis, 2015, 13, 1823-1832.	3.8	62
57	Risk of venous and arterial thrombotic events in patients diagnosed with superficial vein thrombosis: a nationwide cohort study. Blood, 2015, 125, 229-235.	1.4	62
58	Recurrent Implantable Cardioverter-Defibrillator Replacement Is Associated with an Increasing Risk of Pocket-Related Complications. PACE - Pacing and Clinical Electrophysiology, 2010, 33, no-no.	1.2	61
59	Association Between Anemia and Cerebral Venous Thrombosis. Stroke, 2015, 46, 2735-2740.	2.0	61
60	Severe coagulation factor V deficiency caused by a 4â€ƒbp deletion in the factor V gene. British Journal of Haematology, 1998, 101, 32-39.	2.5	60
61	Type-Specific Risk Factors and Outcome in an Outbreak With 2 Different Clostridium difficile Types Simultaneously in 1 Hospital. Clinical Infectious Diseases, 2011, 53, 860-869.	5.8	60
62	Coagulation Abnormalities in Legg-CalvÃ©-Perthes Disease. Journal of Bone and Joint Surgery - Series A, 2010, 92, 121-128.	3.0	59
63	Risk Factors for Cerebral Venous Thrombosis. Seminars in Thrombosis and Hemostasis, 2016, 42, 622-631.	2.7	59
64	Influence of Gender on Ischemic Times and Outcomes After ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2013, 111, 312-318.	1.6	56
65	Contrast-induced acute kidney injury and clinical outcomes after intra-arterial and intravenous contrast administration: Risk comparison adjusted for patient characteristics by design. American Heart Journal, 2013, 165, 793-799.e1.	2.7	55
66	The risk of venous thrombosis in individuals with a history of superficial vein thrombosis and acquired venous thrombotic risk factors. Blood, 2013, 122, 4264-4269.	1.4	54
67	Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study. Blood, 2011, 118, 4239-4241.	1.4	52
68	Current and future burden of venous thrombosis: Not simply predictable. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 199-208.	2.3	52
69	Prediction of hemorrhagic and thrombotic events in patients with mechanical heart valve prostheses treated with oral anticoagulants. Journal of Thrombosis and Haemostasis, 2008, 6, 451-456.	3.8	51
70	Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. European Heart Journal, 2018, 39, 1740-1747.	2.2	51
71	Belowâ€knee cast immobilization and the risk of venous thrombosis: results from a large populationâ€based caseâ€"control study. Journal of Thrombosis and Haemostasis, 2014, 12, 1461-1469.	3.8	49
72	Cancer and risk of cerebral venous thrombosis: a caseâ€"control study. Journal of Thrombosis and Haemostasis, 2018, 16, 90-95.	3.8	48

#	Article	IF	Citations
73	Risk and Risk Factors Associated With Recurrent Venous Thromboembolism Following Surgery in Patients With History of Venous Thromboembolism. JAMA Network Open, 2019, 2, e193690.	5.9	47
74	Risk of thrombotic complications in influenza versus COVIDâ€19 hospitalized patients. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 412-420.	2.3	47
75	Role of Hemostatic Factors on the Risk of Venous Thrombosis in People With Impaired Kidney Function. Circulation, 2014, 129, 683-691.	1.6	46
76	Continuation of lowâ€molecularâ€weight heparin treatment for cancerâ€related venous thromboembolism: a prospective cohort study in daily clinical practice. Journal of Thrombosis and Haemostasis, 2017, 15, 74-79.	3.8	45
77	Pneumonia and risk of venous thrombosis: results from the MEGA study. Journal of Thrombosis and Haemostasis, 2012, 10, 1179-1182.	3.8	44
78	Role of Obesity in the Etiology of Deep Vein Thrombosis and Pulmonary Embolism: Current Epidemiological Insights. Seminars in Thrombosis and Hemostasis, 2013, 39, 533-540.	2.7	44
79	Genetic Variations Associated With Recurrent Venous Thrombosis. Circulation: Cardiovascular Genetics, 2014, 7, 806-813.	5.1	44
80	Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population â€“ results from the HUNT 2 study. British Journal of Haematology, 2008, 141, 529-535.	2.5	43
81	The spatial QRS-T angle in the Frank vectorcardiogram: accuracy of estimates derived from the 12-lead electrocardiogram. Journal of Electrocardiology, 2010, 43, 294-301.	0.9	43
82	Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach. European Heart Journal, 2011, 32, 2678-2687.	2.2	43
83	Randomised trial of no hydration vs. sodium bicarbonate hydration in patients with chronic kidney disease undergoing acute computed tomography-pulmonary angiography. Journal of Thrombosis and Haemostasis, 2014, 12, 1658-1666.	3.8	41
84	Risk of venous thrombosis after arthroscopy of the knee: results from a large populationâ€based caseâ€“control study. Journal of Thrombosis and Haemostasis, 2015, 13, 1441-1448.	3.8	41
85	Alterations in coagulation and fibrinolysis after levothyroxine exposure in healthy volunteers: a controlled randomized crossover study. Journal of Thrombosis and Haemostasis, 2011, 9, 1816-1824.	3.8	40
86	Risk of venous thrombosis in patients with chronic kidney disease: identification of high-risk groups. Journal of Thrombosis and Haemostasis, 2013, 11, 627-633.	3.8	40
87	A randomized comparison of 1-h sodium bicarbonate hydration versus standard peri-procedural saline hydration in patients with chronic kidney disease undergoing intravenous contrast-enhanced computerized tomography. Nephrology Dialysis Transplantation, 2014, 29, 1029-1036.	0.7	40
88	Optimal Level of Oral Anticoagulant Therapy for the Prevention of Arterial Thrombosis in Patients With Mechanical Heart Valve Prostheses, Atrial Fibrillation, or Myocardial Infarction. Archives of Internal Medicine, 2009, 169, 1203.	3.8	39
89	The impact of initial cancer stage on the incidence of venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) Cohort. Journal of Thrombosis and Haemostasis, 2017, 15, 1567-1575.	3.8	39
90	Postpartum Period Is a Risk Factor for Cerebral Venous Thrombosis. Stroke, 2019, 50, 501-503.	2.0	39

#	Article	IF	Citations
91	Effect of No Prehydration vs Sodium Bicarbonate Prehydration Prior to Contrast-Enhanced Computed Tomography in the Prevention of Postcontrast Acute Kidney Injury in Adults With Chronic Kidney Disease. JAMA Internal Medicine, 2020, 180, 533.	5.1	39
92	The effect of flightâ€related behaviour on the risk of venous thrombosis after air travel. British Journal of Haematology, 2009, 144, 425-429.	2.5	38
93	Impact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseases. Circulation, 2014, 129, 855-863.	1.6	38
94	Venous thromboembolism and subsequent permanent workâ€related disability. Journal of Thrombosis and Haemostasis, 2016, 14, 1978-1987.	3.8	38
95	Effect of elevated levels of coagulation factors on the risk of venous thrombosis in long-distance travelers. Blood, 2009, 113, 2064-2069.	1.4	37
96	Hyperhomocysteinemia and Risk of First Venous Thrombosis: The Influence of (Unmeasured) Confounding Factors. American Journal of Epidemiology, 2018, 187, 1392-1400.	3.4	36
97	Early Reperfusion Therapy Affects Inducibility, Cycle Length, and Occurrence of Ventricular Tachycardia Late After Myocardial Infarction. Circulation: Arrhythmia and Electrophysiology, 2011, 4, 195-201.	4.8	35
98	Risk of a Recurrent Cardiovascular Event in Individuals With Type 2 Diabetes or Intermediate Hyperglycemia. Diabetes Care, 2013, 36, 3498-3502.	8.6	35
99	Prehospital use in emergency patients of a laryngeal mask airway by ambulance paramedics is a safe and effective alternative for endotracheal intubation. Emergency Medicine Journal, 2014, 31, 750-753.	1.0	35
100	High levels of procoagulant factors mediate the association between free thyroxine and the risk of venous thrombosis: the MEGA study. Journal of Thrombosis and Haemostasis, 2014, 12, 839-846.	3.8	35
101	Venous Thrombosis Risk after Cast Immobilization of the Lower Extremity: Derivation and Validation of a Clinical Prediction Score, L-TRiP(cast), in Three Population-Based Caseâ€"Control Studies. PLoS Medicine, 2015, 12, e1001899.	8.4	35
102	Lipid levels and risk of venous thrombosis: results from the MEGA-study. European Journal of Epidemiology, 2017, 32, 669-681.	5.7	35
103	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. PLoS ONE, 2014, 9, e94420.	2.5	35
104	Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. Journal of Internal Medicine, 1999, 245, 369-374.	6.0	34
105	Atypical aetiology in patients hospitalised with community-acquired pneumonia is associated with age, gender and season; a data-analysis on four Dutch cohorts. BMC Infectious Diseases, 2016, 16, 299.	2.9	34
106	Relationship between neighborhood socioeconomic status and venous thromboembolism: results from a populationâ€based study. Journal of Thrombosis and Haemostasis, 2017, 15, 2352-2360.	3.8	33
107	Prophylactic implantable cardioverter-defibrillator treatment in the elderly: therapy, adverse events, and survival gain. Europace, 2012, 14, 66-73.	1.7	32
108	Fluid loss does not explain coagulation activation during air travel. Thrombosis and Haemostasis, 2008, 99, 1053-1059.	3.4	31

#	Article	IF	Citations
109	High hematocrit as a risk factor for venous thrombosis. Cause or innocent bystander?. Haematologica, 2010, 95, 182-184.	3.5	31
110	Diversity and Clinical Impact of Acinetobacter baumannii Colonization and Infection at a Military Medical Center. Journal of Clinical Microbiology, 2011, 49, 159-166.	3.9	31
111	Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP). PLoS Medicine, 2019, 16, e1002883.	8.4	31
112	Venous thrombosis following lower-leg cast immobilization and knee arthroscopy: From a population-based approach to individualized therapy. Thrombosis Research, 2019, 174, 62-75.	1.7	31
113	Hypertensive Complications of Pregnancy and Risk of Venous Thromboembolism. Hypertension, 2020, 75, 781-787.	2.7	31
114	Five-year clinical follow-up from the MISSION! Intervention Study: sirolimus-eluting stent versus bare metal stent implantation in patients with ST-segment elevation myocardial infarction, a randomised controlled trial. EuroIntervention, 2012, 7, 1021-1029.	3.2	30
115	Coagulopathy after hemorrhagic traumatic brain injury, an observational study of the incidence and prognosis. Acta Neurochirurgica, 2020, 162, 329-336.	1.7	29
116	Hypofibrinolysis as a risk factor for recurrent venous thrombosis; results of the LETS followâ€up study. Journal of Thrombosis and Haemostasis, 2010, 8, 605-607.	3.8	28
117	The relationship between body mass index, activated proteinÂC resistance and risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 1761-1767.	3.8	28
118	Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancerâ€associated venous thromboembolism during anticoagulant treatment. Journal of Thrombosis and Haemostasis, 2013, 11, 1968-1976.	3.8	28
119	Increased risk of CVD after VT is determined by common etiologic factors. Blood, 2013, 121, 4948-4954.	1.4	28
120	Pulse wave velocity and flow in the carotid artery versus the aortic arch: Effects of aging. Journal of Magnetic Resonance Imaging, 2014, 40, 287-293.	3.4	28
121	Predictors, time course, and outcomes of persistence patterns in oral anticoagulation for non-valvular atrial fibrillation: a Dutch Nationwide Cohort Study. European Heart Journal, 2021, 42, 4126-4137.	2.2	28
122	Influence of the vectorcardiogram synthesis matrix on the power of the electrocardiogram-derived spatial QRS-T angle to predict arrhythmias in patients with ischemic heart disease and systolic left ventricular dysfunction. Journal of Electrocardiology, 2011, 44, 410-415.	0.9	27
123	Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. Journal of Thrombosis and Haemostasis, 2015, 13, 1815-1822.	3.8	27
124	COVIDâ€19 associated coagulopathy and thromboembolic disease: Commentary on an interim expert guidance. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 439-445.	2.3	27
125	Statins and Risk of Bleeding: An Analysis to Evaluate Possible Bias Due to Prevalent Users and Healthy User Aspects. American Journal of Epidemiology, 2016, 183, 930-936.	3.4	26
126	Nationwide claims data validated for quality assessments in acute myocardial infarction in the Netherlands. Netherlands Heart Journal, 2018, 26, 13-20.	0.8	26

#	Article	IF	Citations
127	Persistence of oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 141-153.	2.3	26
128	Effect of genderâ€affirming hormone use on coagulation profiles in transmen and transwomen. Journal of Thrombosis and Haemostasis, 2021, 19, 1029-1037.	3.8	26
129	Explanations for coagulation activation after air travel. Journal of Thrombosis and Haemostasis, 2010, 8, 971-978.	3.8	25
130	The incidence of venous thromboembolism in patients with overt hyperthyroidism. Thrombosis and Haemostasis, 2012, 107, 417-422.	3.4	25
131	Major bleeding risks of different lowâ€molecularâ€weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. Journal of Thrombosis and Haemostasis, 2017, 15, 1386-1391.	3.8	25
132	Rosuvastatin use reduces thrombin generation potential in patients with venous thromboembolism: a randomized controlled trial. Journal of Thrombosis and Haemostasis, 2019, 17, 319-328.	3.8	25
133	Increased levels of free thyroxine and risk of venous thrombosis in a large populationâ€based prospective study. Journal of Thrombosis and Haemostasis, 2012, 10, 1539-1546.	3.8	24
134	Body height, mobility, and risk of first and recurrent venous thrombosis. Journal of Thrombosis and Haemostasis, 2015, 13, 548-554.	3.8	24
135	Sexâ€specific differences in the presenting location of a first venous thromboembolism. Journal of Thrombosis and Haemostasis, 2017, 15, 1344-1350.	3.8	24
136	Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. Journal of Thrombosis and Haemostasis, 2006, 4, 2373-2376.	3.8	23
137	The effect of changes in thyroxine and thyroidâ€stimulating hormone levels on the coagulation system. Journal of Thrombosis and Haemostasis, 2010, 8, 2823-2826.	3.8	23
138	Elevated levels of factor VIII and subsequent risk of allâ€cause mortality: results from the MEGA followâ€up study. Journal of Thrombosis and Haemostasis, 2015, 13, 1833-1842.	3.8	23
139	Warfarin and Aspirin after Heart-Valve Replacement. New England Journal of Medicine, 1994, 330, 507-509.	27.0	22
140	Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA followâ€up study. Journal of Thrombosis and Haemostasis, 2018, 16, 680-688.	3.8	22
141	Venous thrombosis: understanding the paradoxes of recurrence. Journal of Thrombosis and Haemostasis, 2013, 11, 161-169.	3.8	21
142	No effect of isolated longâ€term supine immobilization or profound prolonged hypoxia on blood coagulation. Journal of Thrombosis and Haemostasis, 2014, 12, 902-909.	3.8	21
143	Disease prevalence dependent failure rate in diagnostic management studies on suspected deep vein thrombosis: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 2270-2273.	3.8	21
144	Pre-infarction angina predicts thrombus burden in patients admitted for ST-segment elevation myocardial infarction. EuroIntervention, 2012, 7, 1396-1405.	3.2	21

#	Article	IF	Citations
145	Existing data sources in clinical epidemiology: the Scandinavian Thrombosis and Cancer Cohort. Clinical Epidemiology, 2015, 7, 401.	3.0	20
146	Prolactin and Venous Thrombosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 672-677.	2.4	19
147	Vitamin supplementation on the risk of venous thrombosis: results from the MEGA case-control study. American Journal of Clinical Nutrition, 2015, 101, 606-612.	4.7	19
148	Epidemiology of venous thromboembolism in hematological cancers: The Scandinavian Thrombosis and Cancer (STAC) cohort. Thrombosis Research, 2017, 158, 157-160.	1.7	19
149	Determinants of impaired renal and vascular function are associated with elevated levels of procoagulant factors in the general population. Journal of Thrombosis and Haemostasis, 2018, 16, 519-528.	3.8	19
150	Importance of Reperfusion Status after Intra-Arterial Thrombectomy for Prediction of Outcome in Anterior Circulation Large Vessel Stroke. Interventional Neurology, 2018, 7, 137-147.	1.8	19
151	Post-thrombotic syndrome: Short and long-term incidence and risk factors. Thrombosis Research, 2019, 177, 102-109.	1.7	19
152	Clinical risk assessment model to predict venous thromboembolism risk after immobilization for lower-limb trauma. EClinicalMedicine, 2020, 20, 100270.	7.1	19
153	Glucocorticoid use and risk of first and recurrent venous thromboembolism: selfâ€controlled caseâ€series and cohort study. British Journal of Haematology, 2021, 193, 1194-1202.	2.5	19
154	Interâ€and intraâ€individual concentrations of direct oral anticoagulants: The KIDOAC study. Journal of Thrombosis and Haemostasis, 2022, 20, 92-103.	3.8	19
155	Pregnancy and travel-related thromboembolism. Thrombosis Research, 2013, 131, S55-S58.	1.7	18
156	Influence of World Thrombosis Day on digital information seeking on venous thrombosis: a Google Trends study. Journal of Thrombosis and Haemostasis, 2016, 14, 2325-2328.	3.8	18
157	Impact of time since diagnosis and mortality rate on cancerâ€associated venous thromboembolism: the Scandinavian Thrombosis and Cancer (STAC) cohort. Journal of Thrombosis and Haemostasis, 2018, 16, 1327-1335.	3.8	18
158	Mortality differences in acute myocardial infarction patients in the Netherlands: The weekend-effect. American Heart Journal, 2018, 205, 70-76.	2.7	18
159	Selfâ€reported therapy adherence and predictors for nonadherence in patients who switched from vitamin K antagonists to direct oral anticoagulants. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 586-593.	2.3	18
160	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. PLoS Medicine, 2020, 17, e1003101.	8.4	18
161	Preventing VTE following total hip and knee arthroplasty: Is prediction the future?. Journal of Thrombosis and Haemostasis, 2021, 19, 41-45.	3.8	18
162	Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors. Thrombosis Research, 2021, 197, 172-178.	1.7	18

#	Article	IF	Citations
163	In-Hospital Major Bleeding and Its Clinical Relevance in Patients With ST Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. American Journal of Cardiology, 2013, 112, 1533-1539.	1.6	17
164	Endogenous sex hormones and risk of venous thromboembolism in young women. Journal of Thrombosis and Haemostasis, 2019, 17, 1297-1304.	3.8	17
165	Travel-related thrombosis. Best Practice and Research in Clinical Haematology, 2012, 25, 345-350.	1.7	16
166	The risk of venous thrombosis after air travel: contribution of clinical risk factors. British Journal of Haematology, 2014, 165, 412-413.	2.5	16
167	Fatal recurrent VTE after anticoagulant treatment for unprovoked VTE: a systematic review. European Respiratory Review, 2018, 27, 180094.	7.1	16
168	Association of apolipoproteins C-I, C-II, C-III and E with coagulation markers and venous thromboembolism risk . Clinical Epidemiology, 2019, Volume 11, 625-633.	3.0	16
169	Venous thromboembolism risk stratification for patients with lower limb trauma and cast or brace immobilization. PLoS ONE, 2019, 14, e0217748.	2.5	16
170	Paroxysmal Finger Haematoma: A Neglected Syndrome. Thrombosis and Haemostasis, 1991, 66, 266-266.	3.4	16
171	Incidence and determinants of thrombotic and bleeding complications in patients with glioblastoma. Journal of Thrombosis and Haemostasis, 2022, 20, 1665-1673.	3.8	16
172	Can we prevent venous thrombosis with statins: an epidemiologic review into mechanism and clinical utility. Expert Review of Hematology, 2016, 9, 1023-1030.	2.2	15
173	Patients who underwent total hip or knee arthroplasty are more physically active than the general Dutch population. Rheumatology International, 2017, 37, 219-227.	3.0	15
174	Patients with early arthritis consume less alcohol than controls, regardless of the type of arthritis. Rheumatology, 2013, 52, 1701-1707.	1.9	14
175	Suspected survivor bias in caseâ€“control studies: stratify on survival time and use a negative control. Journal of Clinical Epidemiology, 2014, 67, 232-235.	5.0	14
176	Recurrent venous thrombosis related to overweight and obesity: results from the MEGA followâ€up study. Journal of Thrombosis and Haemostasis, 2017, 15, 1430-1435.	3.8	14
177	Caging the dragon: Research approach to COVIDâ€19â€“related thrombosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, 278-290.	2.3	14
178	Hospital-acquired anemia: the contribution of diagnostic blood loss. Journal of Thrombosis and Haemostasis, 2015, 13, 1157-1159.	3.8	13
179	Statin Therapy to Revert Hypercoagulability and Prevent Venous Thromboembolism: A Narrative Review. Seminars in Thrombosis and Hemostasis, 2019, 45, 825-833.	2.7	13
180	Cardiovascular risk in young apparently healthy descendents from Asian Indian migrants in the Netherlands: the SHIVA study. Netherlands Heart Journal, 2009, 17, 155-161.	0.8	12

#	Article	IF	Citations
181	The incidence of venous thromboembolism in commercial airline pilots: a cohort study of 2630 pilots. Journal of Thrombosis and Haemostasis, 2014, 12, 1260-1265.	3.8	12
182	Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors. Journal of Thrombosis and Haemostasis, 2016, 14, 1572-1578.	3.8	12
183	Lipid levels and risk of recurrent venous thrombosis: results from the MEGA followâ€up study. Journal of Thrombosis and Haemostasis, 2017, 15, 695-701.	3.8	12
184	Antibiotic use as a marker of acute infection and risk of first and recurrent venous thrombosis. British Journal of Haematology, 2017, 176, 961-970.	2.5	12
185	Individualized Thromboprophylaxis in Patients with Lower-Leg Cast Immobilizationâ€"A Validation and Subgroup Analysis in the POT-CAST Trial. Thrombosis and Haemostasis, 2019, 119, 1508-1516.	3.4	12
186	Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns. Journal of Thrombosis and Haemostasis, 2020, 18, 1390-1397.	3.8	12
187	The joint effect of genetic risk factors and different types of combined oral contraceptives on venous thrombosis risk. British Journal of Haematology, 2020, 191, 90-97.	2.5	12
188	Randomized trial of one-hour sodium bicarbonate vs standard periprocedural saline hydration in chronic kidney disease patients undergoing cardiovascular contrast procedures. PLoS ONE, 2018, 13, e0189372.	2.5	12
189	Levels of prolactin in relation to coagulation factors and risk of venous thrombosis. Thrombosis and Haemostasis, 2012, 108, 499-507.	3.4	11
190	Increased risk of major bleeding after a minor bleed during treatment with vitamin K antagonists is determined by fixed common risk factors. Journal of Thrombosis and Haemostasis, 2016, 14, 948-952.	3.8	11
191	Application and comparison of the FADES, MADIT, and SHFM-D risk models for risk stratification of prophylactic implantable cardioverter-defibrillator treatment. Europace, 2017, 19, 72-80.	1.7	11
192	Statin use and risk of recurrent venous thrombosis: results from the MEGA followâ€up study. Research and Practice in Thrombosis and Haemostasis, 2017, 1, 112-119.	2.3	11
193	Erythropoiesis-stimulating agents and cardiovascular events in patients with myelodysplastic syndrome and multiple myeloma. Clinical Epidemiology, 2018, Volume 10, 1371-1380.	3.0	11
194	Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 689-695.	2.3	11
195	Validation of risk assessment models for venous thrombosis in hospitalized medical patients. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 217-225.	2.3	11
196	Glucose levels and diabetes are not associated with the risk of venous thrombosis: results from the <scp>MEGA</scp> caseâ€control study. British Journal of Haematology, 2019, 184, 431-435.	2.5	11
197	More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism. Thrombosis Research, 2020, 196, 435-436.	1.7	11
198	Coffee consumption is associated with a reduced risk of venous thrombosis that is mediated through hemostatic factor levels. Journal of Thrombosis and Haemostasis, 2012, 10, 2519-2525.	3.8	10

#	Article	IF	Citations
199	Theme 2: Epidemiology, Biomarkers, and Imaging of Venous Thromboembolism (and postthrombotic) Tj ETQq1 1 0.784314 rgBT /Overlo	1.7	10
200	The course of pain and function in osteoarthritis and timing of arthroplasty: the CHECK cohort. Monthly Notices of the Royal Astronomical Society: Letters, 2018, 89, 528-534.	3.3	10
201	Factor V levels and risk of venous thrombosis: The MEGA caseâ€control study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 320-326.	2.3	10
202	An observational study on survival rates of patients with out-of-hospital cardiac arrest in the Netherlands after improving the 'chain of survival'. BMJ Open, 2019, 9, e029254.	1.9	10
203	Predictors of response to intramyocardial bone marrow cell treatment in patients with refractory angina and chronic myocardial ischemia. International Journal of Cardiology, 2014, 175, 539-544.	1.7	9
204	The increased risk of venous thromboembolism by advancing age cannot be attributed to the higher incidence of cancer in the elderly: the TromsÃ¸ study. European Journal of Epidemiology, 2014, 29, 277-284.	5.7	9
205	Multi-dose drug dispensing as a tool to improve medication adherence: A study in patients using vitamin K antagonists. Pharmacoepidemiology and Drug Safety, 2018, 27, 46-51.	1.9	9
206	High risk of recurrent venous thrombosis in patients with lower-leg cast immobilization. Journal of Thrombosis and Haemostasis, 2018, 16, 2218-2222.	3.8	9
207	Major Haemorrhage during Vitamin K Antagonist Treatment: The Influence of Thyroid Hormone Levels. European Thyroid Journal, 2014, 3, 32-37.	2.4	8
208	Higher Adherence to Treatment With Lowâ€Molecularâ€Weightâ€Heparin Nadroparin Than Enoxaparin Because of Side Effects in Cancerâ€Associated Venous Thromboembolism. HemaSphere, 2018, 2, e19.	2.7	8
209	The association between leptin concentration and blood coagulation: Results from the NEO study. Thrombosis Research, 2020, 188, 44-48.	1.7	8
210	Current clinical practice for thromboprophylaxis management in patients with Cushingâ€™s syndrome across reference centers of the European Reference Network on Rare Endocrine Conditions (Endo-ERN). Orphanet Journal of Rare Diseases, 2022, 17, 178.	2.7	8
211	Contribution of high factor VIII, IX and XI to the risk of recurrent venous thrombosis in factor V Leiden carriers. Journal of Thrombosis and Haemostasis, 2009, 7, 1944-1946.	3.8	7
212	The ERIKA trial: still limited evidence on the efficacy of thromboprophylaxis after knee arthroscopy. Thrombosis and Haemostasis, 2016, 116, 1001.	3.4	7
213	Predicting the risk of recurrent venous thrombosis: What the future might bring. Journal of Thrombosis and Haemostasis, 2019, 17, 1522-1526.	3.8	7
214	Risk prediction of recurrent venous thrombosis; where are we now and what can we add?. Journal of Thrombosis and Haemostasis, 2019, 17, 1527-1534.	3.8	7
215	Design and rationale of DUTCH-AF: a prospective nationwide registry programme and observational study on long-term oral antithrombotic treatment in patients with atrial fibrillation. BMJ Open, 2020, 10, e036220.	1.9	7
216	Population-based 10-year cumulative revision risks after hip and knee arthroplasty for osteoarthritis to inform patients in clinical practice: a competing risk analysis from the Dutch Arthroplasty Register. Monthly Notices of the Royal Astronomical Society: Letters, 2021, 92, 280-284.	3.3	7

#	Article	IF	Citations
217	Switching from vitamin K antagonists to direct oral anticoagulants in nonâ€valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?. Journal of Thrombosis and Haemostasis, 2022, 20, 339-352.	3.8	7
218	Nonsustained Ventricular Tachycardia Is Independently Associated With Sustained Ventricular Arrhythmias in Nonischemic Dilated Cardiomyopathy. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121009979.	4.8	7
219	Sexâ€specific aspects of venous thromboembolism: What is new and what is next?. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12722.	2.3	7
220	Travel and Venous Thrombosis: An Exercise in Thinking About Bias. Annals of Internal Medicine, 2009, 151, 212.	3.9	6
221	Surveillance of Second-Degree Relatives from Melanoma Families with a CDKN2A Germline Mutation. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1771-1777.	2.5	6
222	Differential risks in men and women for first and recurrent venous thrombosis: the role of genes and environment: reply. Journal of Thrombosis and Haemostasis, 2015, 13, 886-887.	3.8	6
223	Platelet reactivity in patients with venous thrombosis who use rosuvastatin: a randomized controlled clinical trial. Journal of Thrombosis and Haemostasis, 2016, 14, 1404-1409.	3.8	6
224	Venous Thrombosis Risk after Arthroscopy of the Knee: Derivation and Validation of the L-TRiP(ascopy) Score. Thrombosis and Haemostasis, 2018, 118, 1823-1831.	3.4	6
225	Association of smoking and cancer with the risk of venous thromboembolism: the Scandinavian Thrombosis and Cancer cohort. Scientific Reports, 2021, 11, 18752.	3.3	6
226	Trigger Factors for Spontaneous Intracerebral Hemorrhage: A Case-Crossover Study. Stroke, 2022, 53, 1692-1699.	2.0	6
227	Mechanical prophylaxis for travellers? thrombosis: a comparison of three interventions that promote venous outflow. Journal of Thrombosis and Haemostasis, 2007, 5, 1556-1567.	3.8	5
228	Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. Journal of Thrombosis and Thrombolysis, 2015, 40, 323-330.	2.1	5
229	Persistence to direct oral anticoagulants for acute venous thromboembolism. Thrombosis Research, 2018, 167, 135-141.	1.7	5
230	High risk of venous thromboembolism after orthopedic surgery in patients with thrombophilia. Journal of Thrombosis and Haemostasis, 2021, 19, 444-451.	3.8	5
231	Targeted proteomics for evaluating risk of venous thrombosis following traumatic lowerâ€leg injury or knee arthroscopy. Journal of Thrombosis and Haemostasis, 2022, 20, 684-699.	3.8	5
232	The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists. Thrombosis and Haemostasis, 2022, 122, 377-385.	3.4	5
233	Coagulation activation during air travel is not initiated via the extrinsic pathway. British Journal of Haematology, 2015, 169, 903-905.	2.5	4
234	Long-Term Incidence of Venous Thromboembolism in Cancer: The Scandinavian Thrombosis and Cancer Cohort. TH Open, 2018, 02, e131-e138.	1.4	4

#	Article	IF	Citations
235	Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiology and Drug Safety, 2021, 30, 1027-1036.	1.9	4
236	Tumorâ€expressed microRNAs associated with venous thromboembolism in colorectal cancer. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12749.	2.3	4
237	Acute splanchnic venous thrombosis: Surgical and medical treatment with special emphasis on new aspects of coagulation disorders. European Journal of Vascular and Endovascular Surgery, 1997, 13, 227-232.	1.5	3
238	High intensity of oral anticoagulant therapy in patients with cerebral haemorrhage: cause or consequence of the bleeding?. British Journal of Haematology, 1997, 96, 497-499.	2.5	3
239	Plasma Levels of Free Thyroxine and Risk of Major Bleeding in Bariatric Surgery. European Thyroid Journal, 2016, 5, 139-144.	2.4	3
240	Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: A comment. Thrombosis and Haemostasis, 2017, 117, 819.	3.4	3
241	Risk of cancer in patients with thyroid disease and venous thromboembolism. Clinical Epidemiology, 2018, Volume 10, 907-915.	3.0	3
242	Hyperhomocysteinaemia and the risk of recurrent venous thrombosis: results from the MEGA followâ€up study. British Journal of Haematology, 2019, 187, 219-226.	2.5	3
243	Association Between Hepatic Triglyceride Content and Coagulation Factors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 3004-3014.	2.4	3
244	Stability of vitamin K antagonist anticoagulation after COVIDâ€19 diagnosis. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12597.	2.3	3
245	Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial. Journal of Thrombosis and Haemostasis, 2022, 20, 877-887.	3.8	3
246	Effect of prolonged sitting on thrombin generation: not evidenced yet: rebuttal. Journal of Thrombosis and Haemostasis, 2003, 1, 2700-2700.	3.8	2
247	Exercise-resembling effects of periodic somatosensory stimulation in heart failure. International Journal of Cardiology, 2013, 168, 3327-3333.	1.7	2
248	Exposure Opportunity: The Advantages of Including Men in Analyses of Female-Related Risk Factors. American Journal of Epidemiology, 2017, 185, 965-973.	3.4	2
249	Thromboprophylaxis after hospital discharge in acutely ill medical patients: need for trials in patients who are at high risk of venous thrombosis. Journal of Thoracic Disease, 2017, 9, 950-952.	1.4	2
250	Illustrated Stateâ€ofâ€theâ€Art Capsules of the ISTH 2021 Congress. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12532.	2.3	2
251	Effectiveness of endolymphatic duct blockage versus endolymphatic sac decompression in patients with intractable MÃ©niÃ¨reâ€™s disease: study protocol for a double-blinded, randomised controlled trial. BMJ Open, 2021, 11, e054514.	1.9	2
252	The Risk of Venous Thrombosis in Different Immigrant Groups in the Netherlands. Blood, 2012, 120, 3393-3393.	1.4	2

#	Article	IF	Citations
253	Sex Differences in Risk Factors, Clinical Presentation, Treatment and Outcomes of Patients Presenting with Acute Pulmonary Embolism. Blood, 2019, 134, 2429-2429.	1.4	2
254	Prevalence, risk factors, and long-term outcomes of cerebral ischemia in hospitalized COVID-19 patients â€“ study rationale and protocol of the CORONIS study: A multicentre prospective cohort study. European Stroke Journal, 0, , 239698732210925.	5.5	2
255	Lower-leg injury and knee arthroscopy have distinct effects on coagulation. Blood Advances, 2022, 6, 5232-5243.	5.2	2
256	Response to Letter Regarding Article, â€œImpact of Incident Venous Thromboembolism on Risk of Arterial Thrombotic Diseasesâ€• Circulation, 2014, 130, e184-5.	1.6	1
257	Cast immobilization of the lower-leg: No indication for thromboprophylactic therapy. Injury, 2017, 48, 2887-2888.	1.7	1
258	Direct oral anticoagulant use and subsequent start of proton pump inhibitors as proxy for gastric complaints. Pharmacoepidemiology and Drug Safety, 2018, 27, 1371-1378.	1.9	1
259	Nutrition and venous thrombosis: An exercise in thinking about survivor bias. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 6-8.	2.3	1
260	The association of genetic variants in the cholesteryl ester transfer protein gene with hemostatic factors and a first venous thrombosis. Journal of Thrombosis and Haemostasis, 2019, 17, 1535-1543.	3.8	1
261	Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study. Thrombosis and Haemostasis, 2020, 120, 525-530.	3.4	1
262	High Soluble Thrombomodulin Is Associated with an Increased Risk of Major Bleeding during Treatment with Oral Anticoagulants: A Caseâ€“Cohort Study. Thrombosis and Haemostasis, 2021, 121, 070-075.	3.4	1
263	Toward a tailored diagnostic standard for future diagnostic studies in pulmonary embolism: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2021, 19, 1834-1835.	3.8	1
264	A Replication Study of Gene Variants Associated with Venous Thrombosis. Results From a Population-Based Nested Case-Cohort Study.. Blood, 2009, 114, 3985-3985.	1.4	1
265	Is Deep-Vein Thrombosis Always the Origin of Pulmonary Embolism? Imaging of Veins with a Total-Body Direct Thrombus MRI Technique. Blood, 2011, 118, 2297-2297.	1.4	1
266	Statin Use and Risk Of Recurrent Venous Thrombosis: Results From The MEGA Follow-Up Study. Blood, 2013, 122, 3623-3623.	1.4	1
267	Atrial fibrillation in patients with a history of cancer and risk of bleeding complications associated with antithrombotic therapy. European Heart Journal, 2021, 42, .	2.2	1
268	The Risk of Venous Thrombosis Related to Increase in Body Mass Index Is Mediated by Factor VIII Induced APC-Resistance.. Blood, 2009, 114, 453-453.	1.4	1
269	The Risk for Venous Thrombosis in Patients with Increased Body Mass Index and Interactions with Other Genetic and Acquired Risk Factors: The MEGA Study. Blood, 2011, 118, 1234-1234.	1.4	1
270	Risk of Venous Thromboembolism in Hematological Malignancies: The Scandinavian Thrombosis and Cancer Cohort. Blood, 2015, 126, 628-628.	1.4	1

#	Article	IF	Citations
271	Effect of lowerâ€leg trauma and knee arthroscopy on procoagulant phospholipidâ€dependent activity. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12729.	2.3	1
272	Plasma levels of Midkine (neurite growth-promoting factor 2) are not associated with plasma fibrinolytic potential or risk of venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 964-966.	3.8	0
273	Risk and prognosis of in-hospital major bleeding after primary percutaneous coronary intervention for ST-elevation myocardial infarction. European Heart Journal, 2013, 34, P2214-P2214.	2.2	0
274	Confounding by Indication: Letter to the Editor. American Journal of Sports Medicine, 2016, 44, NP12-NP12.	4.2	0
275	Letter to the editor: Does long-term use of analgesics increase the risk of radiographic progression of knee osteoarthritis and future total knee replacement?. Osteoarthritis and Cartilage, 2017, 25, e1-e2.	1.3	0
276	Role of Routine Laboratory Tests in Assessing Risk of Recurrent Venous Thrombosis: Results from the MEGA Follow-Up Study. Thrombosis and Haemostasis, 2018, 118, 1918-1929.	3.4	0
277	The (T) thrombosis (I) in patients with (L) lower (L) limb (I) injuries (R)requiring (I) immobilisation (TILLIRI) study: A prospective observational multicentre study. Thrombosis Update, 2020, 1, 100018.	0.9	0
278	P14.01 Incidence and impact of venous thromboembolism and major bleeding in patients with glioblastoma. Neuro-Oncology, 2021, 23, ii38-ii38.	1.2	0
279	The Association Between Atherosclerosis and Venous Thrombosis: Results From the TromsÃ¸ Study.. Blood, 2012, 120, 2245-2245.	1.4	0
280	Risk of Venous Thrombosis Associated with White Cell Count On Peripheral Blood and Its Interrelationship with Other Environmental Risk Factors. Blood, 2012, 120, 1149-1149.	1.4	0
281	Association of Risk of Incident and Recurrent Venous Thromboembolism with Oral Glucocorticoid Treatment. Blood, 2018, 132, 420-420.	1.4	0
282	Thromboprophylaxis in temporary lower limb immobilization: Extrapolate with care. Journal of Thrombosis and Haemostasis, 2020, 18, 518-519.	3.8	0
283	Antithrombotic therapy and bleeding complications in patients with atrial fibrillation and active cancer. European Heart Journal, 2021, 42, .	2.2	0
284	Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. Blood, 2021, 138, 776-776.	1.4	0
285	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
286	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
287	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0
288	Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study. , 2020, 17, e1003101.		0